Role of natural killer cell subsets in cardiac allograft rejection
- Authors
- McNerney, ME; Lee, KM; Zhou, P; Molinero, L; Mashayekhi, M; Guzior, D; Sattar, H; Kuppireddi, S; Wang, CR; Kumar, V; Alegre, ML
- Issue Date
- 3월-2006
- Publisher
- WILEY
- Keywords
- costimulation; mouse; NK cells; tolerance; transplantation
- Citation
- AMERICAN JOURNAL OF TRANSPLANTATION, v.6, no.3, pp.505 - 513
- Indexed
- SCIE
SCOPUS
- Journal Title
- AMERICAN JOURNAL OF TRANSPLANTATION
- Volume
- 6
- Number
- 3
- Start Page
- 505
- End Page
- 513
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/123157
- DOI
- 10.1111/j.1600-6143.2005.01226.x
- ISSN
- 1600-6135
- Abstract
- To achieve donor-specific immune tolerance to allogeneic organ transplants, it is imperative to understand the cell types involved in acute allograft rejection. In wild-type mice, CD4(+) T cells are necessary and sufficient for acute rejection of cardiac allografts. However, when T-cell responses are suboptimal, such as in mice treated with costimulation-targeting agents or in CD28-deficient mice, and perhaps in transplanted patients taking immunosuppressive drugs, the participation of other lymphocytes such as CD8(+) T cells and NK1.1(+) cells becomes apparent. We found that host NK but not NKT cells were required for cardiac rejection. Ly49G2(+) NK cells suppressed rejection, whereas a subset of NK cells lacking inhibitory Ly49 receptors for donor MHC class I molecules was sufficient to promote rejection. Notably, rejection was independent of the activating receptors Ly49D and NKG2D. Finally, our experiments supported a mechanism by which NK cells promote expansion and effector function of alloreactive T cells. Thus, therapies aimed at specific subsets of NK cells may facilitate transplantation tolerance in settings of impaired T-cell function.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.